IMM
NEUTRALImmuPharma Announces Change in Shareholding
The biopharmaceutical company has announced a change in its major shareholding.
ImmuPharma
2.1700GBX
-3.56%
Market Cap
9.04M
Volume
909.08k
43% of avg
P/E Ratio
-0.01
EPS (TTM)
-3.39
Beta
2.61
Day Range
2.1200p - 2.3700p
52 Week Range
0.8500p2.1700p7.4000p
2.1700p
Upcoming Events
IMM
NEUTRALImmuPharma Announces AGM and Annual Report
The biopharmaceutical company has announced the details of its upcoming Annual General Meeting and the availability of its Annual Report and Accounts.
IMM
NEUTRALImmuPharma Reports Progress in P140 Research Amid Continued Losses
The biopharmaceutical firm reported advancements in its P140 autoimmune research program, alongside reduced annual losses. However, cash reserves remain low, highlighting ongoing financial challenges in its pre-revenue stage.
IMM
NEUTRALImmuPharma Extends Warrants in Incanthera to 2025
The biopharmaceutical company has agreed to extend the exercise period of warrants in Incanthera plc to September 2025.
IMM
NEUTRALImmuPharma to Attend Bio-Europe Spring Conference in Milan
The biopharmaceutical company will be present at the upcoming Bio-Europe Spring conference in Milan, providing networking opportunities.
IMM
NEUTRALImmuPharma Provides Update on P140 Mechanism of Action
The biopharmaceutical company has announced new findings that provide evidence for the unique mechanism of action of its P140 autoimmune technology platform.
IMM
NEUTRALImmuPharma Announces Change in Major Shareholding
The biotechnology company has announced a change in major shareholding, with an institutional investor increasing their stake.
IMM
NEUTRALImmuPharma Raises £2.91m in Oversubscribed Fundraise
The biopharmaceutical company has raised £2.91 million through an oversubscribed placing and subscription, with funds to be used for further investment in its autoimmune technology platform and general working capital.
IMM
GOODImmuPharma Announces Breakthrough Autoimmune Research
The biopharmaceutical company announces groundbreaking progress in its autoimmune disease research, positioning it for potential partnerships and commercialization opportunities.
IMM
GOODImmuPharma Announces Breakthrough Findings in Autoimmune Disease Research
The biopharmaceutical company has made breakthrough discoveries in its research on autoimmune disease mechanisms, which could lead to advancements in diagnostics and personalized treatments.